Astellas Pharma Inc.and FibroGen, Inc. announced that the European Commission (EC) has approved Evrenzo (roxadustat) for the treatment of adult patients with symptomatic anemia associated with chronic kidney… read more.
Researchers report that patients diagnosed with type 2 diabetes in their youth are, by young adulthood, at risk of serious complications. The findings from the TODAY2 study (Treatment… read more.
The FDA has issued a complete response letter (CRL) regarding the New Drug Application (NDA) for roxadustat for the treatment of anaemia of chronic kidney disease (CKD), in… read more.
Immune cells called natural killer cells contribute to organ rejection after transplantation because they miss “self” proteins on donor cells, according to a study appearing in an upcoming… read more.
In a study of adults with normal kidney function, those who had frequent depressive symptoms were more likely to later experience a rapid decline in kidney function. The… read more.
GlaxoSmithKline plc announced positive headline results from five studies of the Phase III ASCEND programme, evaluating the efficacy and safety profile of daprodustat, an investigational oral hypoxia-inducible factor… read more.
University of California – San Diego In mouse models of human disease, immunotoxins targeting the protein mesothelin prevent liver cells from producing collagen, a precursor to fibrosis and… read more.
Bayer announced the FDA has approved Kerendia (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death,… read more.
The European Medicine Agency’s key decision-making committee on human medicines (CHMP), has recommended eight medicines for approval at its June meeting. The Committee recommended granting a conditional marketing authorisation for Abecma… read more.
Diurnal Group plc announces that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Marketing Authorisation for Efmody (hydrocortisone modified-release hard capsules – development name… read more.
Advicenne announces that the Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Sibnayal (ADV 7103) in the UK, for the treatment of distal renal… read more.
Hansa Biopharma, announced three-year follow-up data in crossmatch positive patients who received imlifidase prior to kidney transplantation. As reported in an article, which has been accepted for publication… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
